GPAT for COVID-19: real-time analysis

Download Image

Post

c19early.org

GPAT for COVID-19

1 study with 243 patients

Serious outcome risk

GPAT

Control

COVID-19 GPAT studies · October 2026

Outcome (studies)

Improvement

Relative risk · 95% CI

All studies (1)−38%

Hospitalization (1)−38%

RCTs (1)−38%

Early (1)−38%

00.511.5+

← GPAT
reduces riskIncreased
risk →

.hmva--anim-stagger .hmva__row{opacity:1}.hmva--anim .hmva__shade{opacity:var(--shade-opacity)}.hmva--anim-stagger .est .ci{transform:translateY(-50%)}.hmva--anim-stagger .est .pt{transform:translate(-50%,-50%)}.hmva--anim-stagger .hmva__bar{transform:none}.hmva--anim-settle .est .pt{left:calc(min(var(--pt), 1.5) / var(--max) * 100%)}.hmva--anim-settle .est .ci{left:calc(var(--lo) / var(--max) * 100%);width:calc((var(--hi) - var(--lo)) / var(--max) * 100%)}.hmva--anim-settle .hmva__bar--drug{width:calc(min(1, var(--rr)) * 100%)}.hmva--anim-settle .hmva__bar--control{width:calc(min(1, 1 / var(--rr)) * 100%)}

Graphene photothermal adjuvant therapy (GPAT) is a device-based physical intervention that utilizes a graphene electrothermal film to deliver far-infrared radiation, investigated for its potential to modulate inflammatory immune response.


Apr 28	An et al., Scientific Reports, doi:10.1038/s41598-026-50266-y	Effects of graphene photothermal adjuvant therapy in patients infected with the Omicron BF.7 variant 2022: a prospective randomized controlled trial
Apr 28	38% higher hospitalization (p=0.02) and 35% worse recovery (p=0.03). RCT 243 mildly symptomatic hospitalized COVID-19 patients (Omicron BF.7 variant) in China showing increased risk with graphene photothermal adjuvant therapy (GPAT). All patients received nebulized N-acetylcysteine and the interaction with..